Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial ...

MALT1 is a clinically validated target for leukemias and lymphomas. It is downstream of the BTK pathway and regulates NF-kB signaling, which is elevated in B-cell malignancies and in patients with ...

Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with ...

The first Korean company granted Breakthrough Therapy Designation (BTD) from the U.S. FDA-Clinical trials and results from a three-year follow-up show significant improvements compared to existing ...

Within the BTK market, we continue to strengthen ... focusing on critical segment pathways and TA-driven therapies supported by various technology platforms. Our R&D productivity has been ...

uniQure says it has reached an agreement with the FDA on a pathway to accelerated approval ... in order to devote its attention to AMT-130. Sanofi's oral BTK inhibitor tolebrutinib is heading ...